---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-204049"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-14T23:52:56.928620+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences to repurchase ~6.9M shares from Matrix Capital at $5.64; reports preliminary cash of $114.7M

## Summary
- Enters stock purchase agreement to repurchase up to 6,922,870 shares from Matrix Capital Master Fund at $5.64 per share, matching equity offering price.
- Repurchase conditioned on closing of equity offering; expected after offering closing. Matrix held 10.8% of outstanding shares pre-transaction.
- Preliminary cash, cash equivalents, and marketable securities as of March 31, 2026: approximately $114.7 million (unaudited).
- Repurchase funded by net proceeds from equity offering exceeding $200M; shares become authorized but unissued.

## SEC filing metadata
- accession: 0001193125-26-204049
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000119312526204049/0001193125-26-204049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000119312526204049/d38347d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-204049
- JSON: https://secwatch.observer/filing/0001193125-26-204049.json
- Plain text: https://secwatch.observer/filing/0001193125-26-204049.txt

## Source-grounded claims
- claim_id: adee0d07b6374fe4fc8d9ba030177d4025b398ec
  claim: Aura Biosciences, Inc. entered into Repurchase Agreement with Matrix Capital Management Master Fund, LP (effective 2026-04-30).
  evidence_excerpt: On April 30, 2026, Aura Biosciences, Inc. (the “Company”) and Matrix Capital Management Master Fund, LP (“Matrix”) entered into a stock purchase agreement (the “Repurchase Agreement”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501796/000119312526204049/0001193125-26-204049-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.